What is HC Wainwright’s Estimate for TSE:MSL Q1 Earnings?

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Merus Labs International in a report released on Monday, March 30th. HC Wainwright analyst A. He anticipates that the specialty pharmaceutical company will earn ($0.56) per share for the quarter. HC Wainwright also issued estimates for Merus Labs International’s Q2 2027 earnings at ($0.60) EPS, Q3 2027 earnings at ($0.64) EPS and Q4 2027 earnings at ($0.70) EPS.

Separately, Cantor Fitzgerald raised shares of Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Strong Buy”.

Merus Labs International Stock Performance

Merus Labs International has a 12 month low of C$0.95 and a 12 month high of C$1.76.

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.